Edgewise (EWTX) CFO receives RSUs and 161,250-share option; small sell-to-cover
Rhea-AI Filing Summary
Edgewise Therapeutics insider transactions: R. Michael Carruthers, identified as Chief Financial Officer and reporting person, reported multiple equity transactions dated 08/12/2025. He acquired 5,781 shares of common stock and simultaneously sold 1,428 shares at an average price of $13.3924 to satisfy tax withholding from vesting restricted stock units. Following these transactions, he beneficially owned 86,162 shares of common stock. The filing also reports derivative awards: 5,781 vested restricted stock units exercisable into common shares, 26,875 newly granted restricted stock units, and a stock option to purchase 161,250 shares at an exercise price of $13.39, with vesting schedules extending through 2035. The transactions were signed by an attorney-in-fact on 08/14/2025.
Positive
- CFO received equity awards (26,875 RSUs and a stock option for 161,250 shares), which aligns management incentives with shareholders
- Sell-to-cover transaction of 1,428 shares was explicitly for tax withholding and not a discretionary sale
- Filing includes clear vesting schedules for RSUs and options, improving transparency
Negative
- Potential dilution from the option covering 161,250 shares and RSU grants which could increase share count if fully exercised/vested
- Exercise price of $13.39 on the large option could lead to future share issuance if stock trades above that level
Insights
TL;DR: CFO received substantial equity awards including a large option grant and RSUs; a small sell-to-cover satisfied tax withholding.
These filings show routine executive compensation activity rather than market-moving insider sales. The acquisition of RSUs and a sizeable stock option for 161,250 shares at a $13.39 exercise price increases potential future dilution but aligns management incentives with shareholders. The reported sell-to-cover of 1,428 shares at an average $13.3924 was to satisfy tax withholding on vested RSUs and does not represent a discretionary exit. Overall, this is a standard combination of equity compensation and minimal tax-related disposition.
TL;DR: Compensation grants follow typical vesting schedules; documentation and disclosure appear complete.
The Form 4 discloses clear vesting terms: RSUs vesting in four annual installments starting either 08/12/2025 or 08/12/2026 depending on the grant, and an option vesting monthly beginning September 12, 2025 with a 2035 expiration. The filing includes a sell-to-cover tax withholding explanation and footnotes about ESPP shares acquired May 15, 2025. Signatory authority by an attorney-in-fact is noted. From a governance perspective, disclosures are specific about quantities, prices and vesting which supports transparency. No material non-disclosed transactions are evident in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 5,781 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 26,875 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 161,250 | $0.00 | -- |
| Exercise | Common Stock | 5,781 | $0.00 | -- |
| Sale | Common Stock | 1,428 | $13.3924 | $19K |
Footnotes (1)
- Includes 795 shares purchased on May 15, 2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
